Eli Lilly’s Ebglyss (lebrikizumab) will require strategic market positioning to differentiate it against more established ...

Eli Lilly and Company has announced FDA approval of EBGLYSS (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis ...

David Risinger’s rating is based on the promising topline data from Eli Lilly’s Phase 3b ADapt trial, which showcased the effectiveness of Ebglyss (lebrikizumab) for patients with moderate-to ...

IL-13 inhibitor Ebglyss (lebrikizumab) has been recommended (PDF) by cost-effectiveness agency NICE for people aged 12 and over with moderate-to-severe atopic dermatitis that has not responded to ...

Almirall said the drug, now given the trade name Ebglyss, should be approved by ... The Spanish pharma has said that lebrikizumab is its most important product launch for several years, and ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The US approval of Eli Lilly’s Ebglyss (lebrikizumab) in September 2024 places the company in a competitive position in the atopic dermatitis (AD) market. AD, also known as eczema, is a chronic ...

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

The new product approvals for Ebglyss and Kisunla, exciting new pipeline data for tirzepatide, donanemab, imlunestrant and lebrikizumab, as well as key milestone achievements in our supply network ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...